Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 123-130

  Jerusalem, G ^a   Beguin, Y ^a   Fassotte, M F ^a   Belhocine, T ^a   Hustinx, R ^a   Rigo, P ^a   Fillet, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

2 fluorine 18 fluoro 2 deoxy D glucose; Follow up; Hodgkin's disease; Positron emission tomography; Radionuclide imaging; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALVAGE THERAPY; SYMPTOM; THYMUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; THYMUS GLAND; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037250291     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg011     Document Type: Article

References (34)

1. Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
2. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma. with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116.
3. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
4. Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
5. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
6. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-1122.
7. Weidmann E, Baican B, Hertel A et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymph 1999; 34: 545-551.
8. Partridge S, Timothy AR, O'Doherty MJ. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatement staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
9. 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.
10. Hueltenschmidt B, Sautter-Bihl ML, Lang O et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302-310.
11. 18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
12. Romer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
13. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618.
14. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 1055-1063.
15. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
16. Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181-1184.
17. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11 (Suppl 1): S147-S150.
18. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
19. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
20. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
21. 18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.
22. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. Br Med J 1997; 314: 343-346.
23. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997; 15: 1123-1130.
24. Khan A, Herman PG, Jojas KA et al. Comparison of CT and chest radiographs in the evaluation of post-therapy lymphoma patients. Eur J Radiol 1989; 9: 96-100.
25. Rahmouni A, Divine M, Lavaud A et al. Role of X-ray computed tomography in the follow-up of the course of Hodgkin's disease. French J Radiol 1993; 74: 99-103. [In French].
26. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
27. Weeks JC, Yeap BY, Canellos GP et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9: 1196-1203.
28. Friedman S, Henry-Amar M, Cosset JM et al. Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease. J Clin Oncol 1988; 6: 596-602.
29. Front D, Bar-Shalom R, Epelbaum R et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med 1993; 34: 2101-2104.
30. Jerusalem G, Beguin Y. Commentary on 'Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography'. Clin Lymphoma 2000; 1: 75-76.
31. Cohen M, Hill CA, Cangir A, Sullivan MP. Thymic rebound after treatment of childhood tumors. Am J Roentgenol 1980; 135: 151-156.
32. Peylan-Ramu N, Haddy TB, Jones E et al. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1800-1806.
33. Patel PM, Alibazoglu H, Ali A et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21: 772-775.
34. Weinblatt ME, Zanzi I, Belakhlef A et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997; 38: 888-890.